Bharat Ticker

Automated news summaries. Not investment advice.

[Bharat Ticker @bharat_ticker]

FAIRCHEM ORGANICS Q1 FY27 EARNINGS CALL: MARGINS RECOVER ABOVE 10% AS CHINESE DUMPING EASES AND IMPORT PRESSURE REDUCES

- Revenue from operations rose 34.4% YoY to Rs. 176 crore in Q1 FY27, with EBITDA of Rs. 18 crore (margin 10.14%) and net profit of Rs. 10 crore; management said the improvement was driven by higher price realisations due to elevated raw material costs and reduced imports; realisation was up ~30% YoY and ~25% QoQ.

- Management guided to maintaining a similar revenue and margin run rate for the remaining three quarters of FY27, targeting capacity utilisation growth of ~5% per quarter from the current ~60%, with a goal to exit FY27 at 70–75% utilisation on existing 80,000 MT capacity.

- The CFO confirmed that an inverted duty structure — raw materials attracting 16.5% duty versus 7.5% on finished goods — creates a structural ~9 percentage-point margin drag; management said the company is too small to meaningfully influence policy and has no expectation of near-term correction.

- A new oleochemical product (specific identity not disclosed) from a 40,000 MT additional capacity line is expected to begin trial runs in Q2 FY27; management said margins on this product "should be better" than current levels but declined to elaborate further; this is separate from the Isostearic acid and EV-battery speculation was explicitly denied.

- Isostearic acid (currently 4% of revenue) faces long customer-approval cycles in cosmetics (Europe and Japan); management said most prospective customers are at steps 4–5 of a 5-step approval process and indicated some positive outcome is expected by end of FY27; the product is described as forward integration from dimer acid and does not affect overall plant utilisation targets.

- In Q&A, management said it would not enter long-term volume or price contracts given market volatility, characterising such contracts as "hara-kiri"; exports currently contribute 7–8% of revenue, with dimer acid and Isostearic acid identified as the primary export products; management noted 7–8 large new international customers have approached the company seeking supply-chain diversification.

[Bharat Ticker @bharat_ticker]

LODHA DEVELOPERS Q1 FY27 EARNINGS CALL: RECORD QUARTER WITH PAT MORE THAN DOUBLING; DATA CENTRE LAND PRICE NEARLY DOUBLES IN 12 MONTHS

- Q1 FY27 delivered record financials: revenue INR 50 billion (+43% YoY), adjusted EBITDA INR 21.5 billion (+79% YoY, margin 43%), and PAT INR 13.7 billion (more than double YoY at 26.9% margin); management cautioned this is at the "favourable end of variance" and that 20% PAT growth (~INR 41 billion) remains an annual, not quarterly, commitment.

- Management reaffirmed full-year pre-sales guidance of INR 240 billion for FY27, with H1 expected at 40%–42% of the full year; Q1 pre-sales were INR 46.3 billion (+4% YoY), deliberately held back as ~one-third of normal quarterly pre-sales from new launches was withheld due to Middle East conflict; Q2 pre-sales guided at INR 50 billion or more, with launches already commenced.

- Data centre land at Palava transacted at ~INR 420 million per acre (Digital Edge India JV), nearly double the ~INR 210 million per acre from transactions in calendar 2025; management said fair market value is closer to INR 650 million per acre and expects to reach that level within ~18 months; land sales contributed ~INR 600 crores to Q1 PAT; overall land sales guided at INR 2,000–3,000 crores annually for several years.

- Data centre park now totals 660 acres with 3 GW of power tie-up; management guided ~150 additional acres to be monetised over 3–4 years at ~INR 600 million per acre (~INR 90 billion in further sales from Phase 1 alone); annuity rental income target remains INR 30 billion+ by FY32 (10x from current ~INR 3 billion run rate), with INR 20 billion+ from data centres, INR 6 billion from retail/offices, and INR 4 billion from warehousing.

- Net debt reduced by INR 4.5 billion in the quarter to under INR 50 billion; net debt-to-equity now ~0.2x against a self-imposed ceiling of 0.5x; average cost of debt stable at 7.8%; management guided DevCo to be net debt-free within 2–3 years; medium-term PAT growth target of ~20% annually, targeting beyond INR 85 billion by FY31.

- In Q&A, management said Middle East NRI buyers represent ~4%–5% of sales and impact remains "contained"; residential embedded margins excluding land sales are in the "early 30s," consistent with full-year guidance; management expects 5%–7% price increases across micro markets in FY27, with the CEO noting a further 100–200 bps lever available on pricing if needed.

[Bharat Ticker @bharat_ticker]

AYE FINANCE EARNINGS CALL: PAT SURGES 144% YOY AS CREDIT COST TRACKS LOWER END OF GUIDANCE IN Q1 FY27

- Management maintained full-year AUM growth guidance of 25%-30% (AUM at INR7,324 crores, up 28% YoY); guided credit cost to 3.5%-4% for FY27, noting Q1's 4.01% is "already at the top of that band" and should improve further; NIM guidance held flat but management flagged potential upside given Q1 NIM improved 20 bps sequentially to 15.9%.
- India Ratings upgraded long-term rating to A+ (from A) and commercial paper to A1+; CFO said incremental borrowing cost is currently ~10.20% and the upgrade is expected to reduce incremental borrowing costs by a further 10-15 bps, on top of ~60 bps already achieved year-on-year.
- Asset quality showed sixth consecutive quarter of improvement: Gross NPA fell 28 bps sequentially to 4.49%; credit cost declined 29 bps sequentially to 4.01%; management said PAR X at 7% is sufficient to deliver guided credit cost range and targets a sustainable PAR X of 6%-6.5% over time.
- Disbursements of INR1,219 crores grew 22% YoY (strongest-ever Q1); 44,000 new borrowers added (up 38% YoY) despite tightening loan approval rate from ~55% to ~45% of cases logged; management plans to add only ~40-50 branches in FY27, targeting ~10% headcount growth to support 25%-30% AUM growth.
- Medium-term targets outlined: AUM of INR24,000 crores within five years (~27%-28% CAGR); mortgage share to reach ~30-35% over time (currently ~22%), which management said could reduce long-term credit cost by ~50 bps to a 3%-3.5% range; opex ratio guided to decline from current 8.9% toward 7%-7.5% over three years.
- On capital adequacy, CFO said current leverage of 3.15x provides runway to grow to ~INR14,000 crores AUM before fresh capital is needed, estimated at 2-2.5 years; management explicitly ruled out aggressive co-lending or DA (DA capped at 5%-7% of AUM strategically) given adequate liquidity and small ticket-size economics.

[Bharat Ticker @bharat_ticker]

RAMKRISHNA FORGINGS EARNINGS CALL: MANAGEMENT TARGETS RS. 8,000 CRORE REVENUE BY FY29 WITH 22-25% CAGR

- Management guided to 22-25% revenue CAGR over three years, with the Rs. 8,000 crore turnover target now pushed to FY29 (delayed by one year from the earlier FY28 target); FY27 export growth guided at 20%-plus, with exports expected to constitute ~35% of consolidated revenue and reach the highest-ever level for the company.

- The CFO guided for ROCE of 12-15% in FY27, rising to ~20% in FY28; the company targets net debt reduction of at least Rs. 500 crores in FY27, bringing net debt from Rs. 1,900 crores to ~Rs. 1,500 crores, with further reduction expected in FY28.

- Q1 FY27 consolidated revenue stood at Rs. 1,217 crores (up ~20% YoY, flat QoQ); EBITDA (ex-other income) at Rs. 218 crores, up 47% YoY and 5% QoQ, with EBITDA margin improving to 17.96% from 17.11% in the prior quarter; PAT at Rs. 46.88 crores versus Rs. 11.7 crores a year ago.

- Capex guidance for FY27 is ~Rs. 350 crores total; management said the majority of strategic capex is now complete, with focus shifting to asset sweating and utilisation improvement; at full capacity the CFO indicated an asset turn of ~2.5x implying ~Rs. 9,000 crores of peak revenue potential.

- Rail wheel JV (RKTR) commenced trial production; 300-piece sample submission to Indian Railways expected in August, with bulk supply targeted from September-October; Mexico facility contributed ~Rs. 6 crores in Q1, with significant revenue from that facility expected from Q3 FY27 onwards; new orders of Rs. 278 crores (auto, 4-year programme life, entirely domestic, ~82% PV/18% two-wheeler) and Rs. 15 crores from the metro/railways segment were secured in Q1.

- On analyst Q&A, management confirmed all currency exposure is passed through to customers on a quarterly basis (no net FX gain or loss); key margin risks identified as energy prices and shipping costs, which cannot be fully passed on, while steel cost increases carry a one-quarter lag before customer pass-through; non-ferrous/aerospace initiative (aluminium bulk production already started; Inconel/titanium meaningful contribution seen at least two years away with only Rs. 10-20 crores near-term capex required).

[Bharat Ticker @bharat_ticker]

RAINBOW CHILDRENS MEDICARE — Q1 FY27 STANDALONE RESULTS

Net Profit - ₹52.71 cr (₹51.72 cr in Q1 FY26, -1.9% YoY)

Revenue - ₹410.55 cr (₹334.75 cr in Q1 FY26, +22.7% YoY)

[Bharat Ticker @bharat_ticker]

3I INFOTECH — CAPITAL NXT LLP AND PERSONS ACTING IN CONCERT CROSS 7% STAKE

Shares Acquired - 7,03,915 shares via open market purchases

Shareholding - 7.08% (up from 6.74% pre-acquisition)

[Bharat Ticker @bharat_ticker]

NIVA BUPA HEALTH INSURANCE — BOARD APPROVES NCD FUNDRAISE OF UP TO ₹500 CRORE

NCD Issue Size - up to ₹500 cr (private placement basis)

[Bharat Ticker @bharat_ticker]

SATIN CREDITCARE NETWORK — Q1 FY27 NET PROFIT UP 78% YoY

Net Profit - ₹3,766.93 lakhs vs ₹2,117.53 lakhs YoY (+78%)

Total Income - ₹67,145.46 lakhs vs ₹63,716.41 lakhs YoY

[Bharat Ticker @bharat_ticker]

THERMAX LIMITED — BOARD APPROVES MERGER OF TWO WHOLLY-OWNED SUBSIDIARIES INTO PARENT

Transferor Companies - Thermax Cooling Solutions Limited and Thermax Bioenergy Solutions Private Limited (wholly-owned subsidiaries)

Demerged Undertaking Turnover - Rs. 239.35 crore (3.67% of total group turnover in FY2026)

Share Issuance - Nil (no new equity shares to be issued; no change in shareholding pattern)

[Bharat Ticker @bharat_ticker]

CHAMBAL FERTILIZERS — Q1 FY27 NET PROFIT DOWN 77.2% YoY

Net Profit - ₹145.39 cr vs ₹637.97 cr YoY (-77.2%)

Revenue - ₹2,785.03 cr vs ₹5,865.86 cr YoY (-52.5%)

[Bharat Ticker @bharat_ticker]

RAIL VIKAS NIGAM LIMITED — SENIOR MANAGEMENT EXIT

Name - Shri Manish Agarwal, Principal Executive Director (Mechanical)

Effective Date - 30 July 2026 (cessation due to repatriation)

[Bharat Ticker @bharat_ticker]

GNG ELECTRONICS — Q1 FY27 NET PROFIT UP 56.5% YoY

Net Profit - ₹159.38 mn vs ₹101.81 mn YoY (+56.5%)

[Bharat Ticker @bharat_ticker]

TRIVENI ENGINEERING & INDUSTRIES — Q1 FY27 CONSOLIDATED NET PROFIT SWINGS TO POSITIVE

Net Profit - ₹3.65 cr vs loss of ₹6.62 cr in Q1 FY26

Revenue - ₹1,950.14 cr (vs ₹1,904.17 cr YoY)

[Bharat Ticker @bharat_ticker]

COLGATE PALMOLIVE INDIA — Q1 FY27 NET PROFIT UP 7% YoY

Net Profit - ₹343.1 cr vs ₹320.6 cr YoY (+7%)

Net Sales - ₹1,590.6 cr vs ₹1,420.6 cr YoY (+12%)

[Bharat Ticker @bharat_ticker]

GLOBAL HEALTH (MEDANTA) — Q1 FY27 NET PROFIT UP 9.7% YoY

Net Profit - ₹1,373.07 mn (vs ₹1,241.31 mn in Q1 FY26, +9.7% YoY)

Revenue - ₹10,787.23 mn (vs ₹8,821.56 mn, +22.3% YoY)

[Bharat Ticker @bharat_ticker]

GARDEN REACH SHIPBUILDERS — WINS ₹1,032.07 CR ONGC ORDER FOR FOUR PLATFORM SUPPLY VESSELS

Order Value - ₹1,032.07 cr

Client - Oil and Natural Gas Corporation (ONGC)

Scope - Construction of 4 Platform Supply Vessels | Execution timeline: 48 months

[Bharat Ticker @bharat_ticker]

SWIGGY LIMITED — Q1 FY27 NET LOSS NARROWS MARGINALLY AS COSTS WEIGH

Net Loss - ₹791 cr vs ₹1,197 cr YoY

Revenue - ₹6,812 cr vs ₹4,961 cr YoY (+37%)

[Bharat Ticker @bharat_ticker]

FISCHER MEDICAL VENTURES — ASSOCIATE NANOMEDIC GETS CDSCO IMPORT APPROVAL FOR SPINCARE WOUND CARE SYSTEM

Approval - CDSCO Permission No. IMP/MD/2026/000455 (Class C medical device; India's first regulatory clearance for electrospun wound care technology)

[Bharat Ticker @bharat_ticker]

BAJAJ FINANCE — Q1 FY27 PAT UP 28% YoY

PAT - ₹6,081 cr (+28% YoY)

AUM - ₹5,46,944 cr (vs ₹4,41,450 cr in Q1 FY26, +24% YoY)

[Bharat Ticker @bharat_ticker]

MANKIND PHARMA — Q1 FY27 NET PROFIT UP 34.5% YoY

Net Profit - ₹558.49 cr vs ₹415.27 cr YoY (+34.5%)

Revenue - ₹2,964.05 cr vs ₹2,569.73 cr YoY (+15.4%)